Glatopa is launched in US as generic Copaxone (glatiramer acetate injection) for MS- Sandoz + Momenta

The US Court of Appeals has finally invalidated patent protection for Teva’s multiple sclerosis drug Copaxone (glatiramer acetate injection) for the second time, clearing the way for Sandoz and Momenta to launch their generic Glatopa on the market. Glatopa is the first generic version of Teva's Copaxone (glatiramer acetate injection) 20 mg/ml once-daily multiple sclerosis therapy.

Comment: Teva now has secured FDA approval for three-times-a-week Copaxone 40mg/ml, a new dose of the drug. This new formulation will allow for a less frequent dosing regimen administered subcutaneously for patients with relapsing forms of Multiple Sclerosis. Teva has secured FDA and EU approvals for the new formulation and has been converting multiple sclerosis patients taking 20mg/ml injections of Copaxone daily to the longer-acting (three times a week) formulation. Over 60% of patients have moved to the new dosage.